Incidence of contrast material-induced nephropathy after neuroendovascular procedures.

PURPOSE: To report the incidence and risk factors for contrast material ( CM contrast material )-induced nephropathy ( CIN CM-induced nephropathy ) in patients with no history of chronic kidney disease and estimated glomerular filtration rate that exceeded 30 mL/min/1.73 m(2) after a relatively high dose of CM contrast material (≥250 mL) during neuroendovascular procedures. MATERIALS AND METHODS: An institutional review board-approved retrospective chart review was performed for all patients who received a dose of CM contrast material 250 mL or greater while they underwent a neuroendovascular procedure between January 2011 and February 2013. The control group consisted of comparable patients who received a CM contrast material dose of 75-249 mL during the same period. Patients with pre-existing estimated glomerular filtration rate of 30 mL/min/1.73 m(2) or less or documented history of chronic kidney disease were excluded. CIN CM-induced nephropathy was defined as an increase in serum creatinine 50% above the baseline or an absolute increase of 0.3 mg/dL at either 24 or 48 hours after the procedure. Statistical analysis was performed with the Student t test, χ(2) analysis, and mixed-model analysis of variance. RESULTS: Clinical characteristics between the control and high-dose group were similar for age (95% confidence interval [CI]: -3.69, 5.48; P = .70), sex (95% CI: 0.28, 0.43; P = .62), and ethnicity (95% CI: 0.42, 0.58; P = .47). The average volume of CM contrast material administered was 172 mL in the control group and 326 mL in the high-dose cohort (95% CI: 131.78, 175.05; P < .001). Of the 79 cases in the high-dose cohort, 36 (46%) received a CM contrast material dose between 250 and 299 mL, 29 (37%) received 300-399 mL, nine (11%) received 400-499 mL, and five (6%) received greater than 500 mL. By 48 hours, a statistically significant decrease in serum creatinine was seen in two of the four high-dose CM contrast material dose categories: 250-299 mL (decrease of 24%; [95% CI: 0.04, 0.36]; P = .003) and greater than 500 mL (decrease of 14% [95% CI: -0.33, 0.57]; P = .007). There were four cases (5%) of CIN CM-induced nephropathy : three (4%) at 24 hours and one (1%) at 48 hours. The comorbid rate of diabetes (25% vs 15% [95% CI: -0.01, 0.04]; P < .001) was found to be higher among those who developed CIN CM-induced nephropathy compared with those who did not within the high-dose cohort. No cases of CIN CM-induced nephropathy occurred in the control group. CONCLUSION: Risk of developing CIN CM-induced nephropathy is relatively low in patients who undergo neuroendovascular procedures with CM contrast material doses of 250 mL or greater.

Missed pulmonary emboli on CT angiography: assessment with pulmonary embolism-computer-aided detection.

OBJECTIVE: The purpose of this study is to assess the use of a pulmonary embolism (PE)- computer-aided detection (CADx) program in the detection of PE missed in clinical practice. MATERIALS AND METHODS: Pulmonary CT angiography (CTA) studies (n = 6769) performed between January 2009 and July 2012 were retrospectively assessed by a thoracic radiologist. In studies that were positive for PE, all prior contrast-enhanced pulmonary CTA studies were reviewed. Missed PE was deemed to have occurred if PE was not described in the final interpretation. The presence, proximal extent, and number of PEs were agreed on by three thoracic radiologists. Studies with missed acute PE and available slice thickness of 2 mm or less were assessed with a prototype PE-CADx program. False-positive PE-CADx marks were analyzed. Outcomes of missed acute PEs were assessed in patients with both follow-up imaging and clinical data. RESULTS: Fifty-three studies with overlooked acute PE met our inclusion criteria for PE-CADx assessment. The PE-CADx program identified at least one PE in 77.4% of instances (41/53). PE-CADx correctly marked at least one PE in 23 of 23 cases (100%) with multiple PEs and 18 of 30 (60%) cases with a solitary PE (p < 0.001). PE-CADx per-study sensitivity was significantly higher for segmental (65.5%) than for subsegmental (91.7%) PEs (p = 0.002). PE-CADx averaged 3.8 false-positive marks per case (range, 0-23 marks). Fourteen patients with missed PE who were not receiving anticoagulation therapy developed new PEs, including nine with an isolated subsegmental PE on the initial CT scan. CONCLUSION: PE-CADx correctly identified 77.4% of cases of acute PE that were previously missed in clinical practice.